Company Analysis PFIZER
1. Summary
Advantages
- Dividends (6.16%) are higher than the sector average (1.32%).
- The stock's return over the last year (-6.05%) is higher than the sector average (-31.87%).
- The company's current efficiency (ROE=2.38%) is higher than the sector average (ROE=-80.86%)
Disadvantages
- Price (25.47 $) is higher than fair price (2.85 $)
- Current debt level 31.97% has increased over 5 years from 31.14%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
18 november 17:29 Vaccine makers see stock price boost on Biden admin COVID shot push
2.3. Market efficiency
| PFIZER | Healthcare | Index | |
|---|---|---|---|
| 7 days | -1.4% | -2.2% | 0.8% |
| 90 days | -2.1% | -33.2% | 3.1% |
| 1 year | -6% | -31.9% | 23.7% |
PFE vs Sector: PFIZER has outperformed the "Healthcare" sector by 25.82% over the past year.
PFE vs Market: PFIZER has significantly underperformed the market by -29.75% over the past year.
Stable price: PFE is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: PFE with weekly volatility of -0.1163% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (25.47 $) is higher than the fair price (2.85 $).
Price is higher than fair: The current price (25.47 $) is 88.8% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (76.52) is lower than that of the sector as a whole (114.5).
P/E vs Market: The company's P/E (76.52) is higher than that of the market as a whole (70.26).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.82) is lower than that of the sector as a whole (9.44).
P/BV vs Market: The company's P/BV (1.82) is lower than that of the market as a whole (22.61).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.77) is lower than that of the sector as a whole (4.13).
P/S vs Market: The company's P/S indicator (2.77) is lower than that of the market as a whole (15.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (22.26) is higher than that of the sector as a whole (17.79).
EV/Ebitda vs Market: The company's EV/Ebitda (22.26) is lower than that of the market as a whole (24.37).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -13.96% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-13.96%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-57.12%).
5.4. ROE
ROE vs Sector: The company's ROE (2.38%) is higher than that of the sector as a whole (-80.86%).
ROE vs Market: The company's ROE (2.38%) is lower than that of the market as a whole (18.07%).
5.5. ROA
ROA vs Sector: The company's ROA (0.9355%) is lower than that of the sector as a whole (6.71%).
ROA vs Market: The company's ROA (0.9355%) is lower than that of the market as a whole (6.49%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (23.27%) is higher than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (23.27%) is higher than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 6.16% is higher than the average for the sector '1.32%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 6.16% has been steadily paid over the past 7 years, DSI=1.
Dividend growth: Company's dividend yield 6.16% has been growing over the last 5 years. Growth over 10 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (436.39%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 30.10.2024 | Gottlieb Scott Director |
Purchase | 28.24 | 28 240 | 1 000 |
| 25.02.2023 | Hwang Angela President, Global Biopharma |
Purchase | 22.89 | 464 049 | 20 273 |
| 25.02.2023 | DAMICO JENNIFER B. SVP & Controller |
Purchase | 22.89 | 255 224 | 11 150 |
| 25.02.2023 | McDermott Michael Executive Vice President |
Purchase | 22.89 | 324 534 | 14 178 |
| 22.02.2023 | DAMICO JENNIFER B. SVP & Controller |
Purchase | 30.17 | 315 458 | 10 456 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
9. Stocks forum PFIZER
9.1. Stocks forum - Latest comments
ΠΠΎΡ, ΠΊΡΡΠ°ΡΠΈ, ΠΏΡΠΎ ΠΡΠ°ΠΉΠ·Π΅Ρ Π³ΠΎΠ²ΠΎΡΡΡ, ΡΡΠΎ Π΄ΠΈΠ²ΠΈΠ΄Π΅Π½Π΄Π½Π°Ρ Π΄ΠΎΡ ΠΎΠ΄Π½ΠΎΡΡΡ Ρ Π½ΠΈΡ Π²ΡΡΠΎΠΊΠ°Ρ, ΡΠΆΠ΅ Π½Π΅ ΠΎΠ΄ΠΈΠ½ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ ΠΌΠ½Π΅ ΠΎΠ± ΡΡΠΎΠΌ ΡΠΊΠ°Π·Π°Π». ΠΡΠΎ ΡΡΠΎ Π·Π½Π°Π΅Ρ?
